CytoSorbents (NASDAQ: CTSO) files 8-K on -ATR regulatory update press release

Rhea-AI Filing Summary

CytoSorbents Corporation furnished a current report stating that it issued a press release providing a regulatory update on its -ATR program. The press release is attached as Exhibit 99.1 and is treated as furnished, not filed, under securities law.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false0001175151true00011751512025-09-162025-09-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 16, 2025

Cytosorbents Corp

(Exact name of registrant as specified in its charter)

Delaware		001-36792		98-0373793
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

305 COLLEGE ROAD EAST PRINCETON, New Jersey		08540
(Address of principal executive offices)		(Zip code)

Registrant's telephone number, including area code (973) 329-8885

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value		NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 16, 2025, CytoSorbents Corporation (the “Company”) issued a press release providing a regulatory update on DrugSorb^TM-ATR.  A copy of the press release is furnished herewith as Exhibit 99.1.*

Item 8.01 Other Events.

The information set forth under “Item 7.01 Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated into this Item 8.01 by reference.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of the Company, dated September 16, 2025
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)

* The information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2025	CYTOSORBENTS CORPORATION
	By:	/s/ Dr. Phillip P. Chan
	Name:	Dr. Phillip P. Chan
	Title:	Chief Executive Officer

FAQ

What did CytoSorbents (CTSO) disclose in this 8-K filing?

CytoSorbents disclosed that it issued a press release providing a regulatory update on its -ATR program. The press release is attached as Exhibit 99.1 and is furnished under Regulation FD, not filed for liability purposes.

What is included as Exhibit 99.1 in CytoSorbents’ 8-K?

Exhibit 99.1 is a press release from CytoSorbents dated September 16, 2025. The press release provides a regulatory update on the company’s -ATR program and is furnished as part of the current report.

How is the CytoSorbents -ATR regulatory update treated under SEC rules?

The -ATR regulatory update is presented in a press release furnished under Item 7.01. The company states this information is not deemed filed under Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.

Which SEC item does the CytoSorbents press release relate to?

The press release is furnished under Item 7.01, Regulation FD Disclosure, and its contents are incorporated by reference into Item 8.01. This structure indicates the update is for public information and disclosure fairness rather than a transactional event.

Who signed the CytoSorbents 8-K related to the -ATR update?

The 8-K was signed on behalf of CytoSorbents Corporation by Dr. Phillip P. Chan. He signed in his capacity as Chief Executive Officer, confirming the company’s authorization of the current report’s contents.

What other exhibit is listed in CytoSorbents’ 8-K besides the press release?

In addition to the press release as Exhibit 99.1, the filing lists Exhibit 104. This exhibit is the cover page interactive data file embedded within the Inline XBRL version of the document, supporting structured data reporting.